Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DME (ID: DE6OQ3W)

• DME Name: Cytochrome P450 1A1 (CYP1A1) DME Info
• Gene Name: CYP1A1

Molecule-Related Drug & Molecule List

44 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[1]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[2]
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[3]
BAY 80-6946	DMLOS5R	Follicular lymphoma	2A80	Approved	[4]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[5]
Chloroquine	DMSI5CB	Malaria	1F40-1F45	Approved	[6]
Clenbuterol	DMCKYZ5	Chronic breathing disorder	7A4Z	Approved	[7]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[8]
Dacarbazine	DMNPZL4	Adenocarcinoma	2D40	Approved	[9]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[10]
Debrisoquin	DMC50ME	Hypertension	BA00-BA04	Approved	[11]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[12]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[13]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[14]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[15]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[16]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[17]
Flunarizine	DMZU5JP	Migraine	8A80	Approved	[8]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[18]
Fluvastatin	DM4MDJY	Arteriosclerosis	BD40	Approved	[19]
Granisetron	DMIUW25	Malignant glioma	2A00.0	Approved	[20]
Haloperidol	DM96SE0	Delirium		Approved	[21]
Ipriflavone	DM0IO13	Osteoporosis	FB83.0	Approved	[22]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[23]
Melatonin	DMKWFBT	Depression	6A70-6A7Z	Approved	[24]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[25]
Mercaptopurine	DMTM2IK	Acute lymphoblastic leukaemia	2A85	Approved	[26]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[27]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[28]
Perazine	DM2AOTZ	Psychotic disorder	6A20-6A25	Approved	[29]
Prazosin	DMCD9YG	Benign prostatic hyperplasia	GA90	Approved	[30]
Procarbazine	DMIK367	Hodgkin lymphoma	2B30	Approved	[31]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[32]
Raltegravir	DMYURI6	Human immunodeficiency virus infection	1C62	Approved	[33]
Retigabine	DMGNYIH	Behcet disease	4A62	Approved	[34]
Riboflavin	DM8YMWE	Acne vulgaris	ED80	Approved	[35]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[36]
Riociguat	DMXBLMP	Chronic thromboembolic pulmonary hypertension		Approved	[37]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[38]
Testosterone cypionate	DMC1TEV	N. A.	N. A.	Approved	[32]
Theophylline	DMRJFN9	Bronchitis	CA20	Approved	[39]
Toremifene	DMQYUWG	Breast cancer	2C60-2C65	Approved	[40]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[41]
ZOTEPINE	DMF3VXA	Anxiety disorder	6B00-6B0Z	Approved	[42]

7 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
5-methoxypsoralen	DME2A8X	Psoriasis vulgaris	EA90	Phase 3	[43]
MK-4827	DMLYGH4	Ovarian cancer	2C73	Phase 3	[44]
AFQ056	DMMHSLC	Fragile X syndrome	LD55	Phase 2/3	[45]
2-Methoxyestradiol	DMGBPME	Pulmonary arterial hypertension	BB01.0	Phase 2	[46]
9-AMINOCAMPTOTHECIN	DMQXYRG	Acquired immune deficiency syndrome	1C62.3	Phase 2	[47]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[48]
SALVINORIN A	DMJ3HQY	Cerebral vasospasm	BA85.Z	Phase 1	[49]

2 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenacetin	DMRQAM0	Analgesia	MB40.8	Withdrawn from market	[50]
Benzydamine	DMEQL9U	Chemotherapy or radiotherapy-induced mucositis	DA42-DA60	Discontinued in Phase 2	[51]

1 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acriflavinium chloride	DMYZJ5B	N. A.	N. A.	Investigative	[52]

References

• [1] Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7.
• [2] A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos. 2000 Nov;28(11):1303-10.
• [3] Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther. 2002 Feb;300(2):399-407.
• [4] FDA label of Copanlisib. The 2020 official website of the U.S. Food and Drug Administration.
• [5] Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
• [6] In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos. 2003 Jun;31(6):748-54.
• [7] Beta-adrenergic receptor modulation of the LPS-mediated depression in CYP1A activity in astrocytes. Biochem Pharmacol. 2005 Mar 1;69(5):741-50.
• [8] Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
• [9] Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin Cancer Res. 1999 Aug;5(8):2192-7.
• [10] The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro. Physiol Res. 2004;53(6):683-91.
• [11] 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine. J Pharmacol Exp Ther. 2002 Jun;301(3):1025-32.
• [12] Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
• [13] Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
• [14] Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
• [15] A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
• [16] Xenobiotic metabolizing and antioxidant enzymes in normal and neoplastic human breast tissue. Eur J Drug Metab Pharmacokinet. 1998 Oct-Dec;23(4):497-500.
• [17] The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004 Nov;32(11):1209-12.
• [18] Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther. 2001 Feb;296(2):537-41.
• [19] Regulation of cytochrome P450 expression by inhibitors of hydroxymethylglutaryl-coenzyme A reductase in primary cultured rat hepatocytes and in rat liver. Drug Metab Dispos. 1996 Nov;24(11):1197-204.
• [20] CYP1A1 is a major enzyme responsible for the metabolism of granisetron in human liver microsomes. Curr Drug Metab. 2005 Oct;6(5):469-80.
• [21] In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab Dispos. 2001 Dec;29(12):1638-43.
• [22] Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous ipriflavone in rats. J Pharm Pharmacol. 2006 Apr;58(4):449-57.
• [23] Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells. Br J Cancer. 2005 Feb 28;92(4):696-704.
• [24] Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
• [25] Rat hepatic CYP1A1 and CYP1A2 induction by menadione. Toxicol Lett. 2005 Feb 15;155(2):253-8.
• [26] Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
• [27] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [28] The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
• [29] The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. Eur Neuropsychopharmacol. 2004 May;14(3):199-208.
• [30] Role of adrenoceptor-linked signaling pathways in the regulation of CYP1A1 gene expression. Biochem Pharmacol. 2005 Jan 15;69(2):277-87.
• [31] In vitro and in vivo evidence for the formation of methyl radical from procarbazine: a spin-trapping study. Carcinogenesis. 1992 May;13(5):799-805.
• [32] Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
• [33] Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients. Ther Drug Monit. 2010 Dec;32(6):782-6.
• [34] Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos. 1999 May;27(5):605-12.
• [35] Disruption of endogenous regulator homeostasis underlies the mechanism of rat CYP1A1 mRNA induction by metyrapone. Biochem J. 1998 Apr 1;331 ( Pt 1):273-81.
• [36] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [37] Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. P T. 2014 Nov;39(11):749-58.
• [38] Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
• [39] Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther. 1993 Apr;265(1):401-7.
• [40] Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem Pharmacol. 1994 May 18;47(10):1883-95.
• [41] Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab Dispos. 1999 Nov;27(11):1260-6.
• [42] Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica. 1999 Mar;29(3):217-29.
• [43] Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity. PLoS One. 2013 Sep 23;8(9):e75494.
• [44] Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009 Nov 26;52(22):7170-85.
• [45] Methods to Assess Pulmonary Metabolism.
• [46] Role of 2-methoxyestradiol, an Endogenous Estrogen Metabolite, in Health and Disease. Mini Rev Med Chem. 2015;15(5):427-38.
• [47] Cytochrome P450 3A-mediated metabolism of the topoisomerase I inhibitor 9-aminocamptothecin: impact on cancer therapy. Int J Oncol. 2014 Aug;45(2):877-86.
• [48] Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
• [49] Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm. 2009 Jun;72(2):471-7.
• [50] Identification of CYP3A4 as the enzyme involved in the mono-N-dealkylation of disopyramide enantiomers in humans. Drug Metab Dispos. 2000 Aug;28(8):937-44.
• [51] In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms. Br J Clin Pharmacol. 2000 Oct;50(4):311-4.
• [52] Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2. Mol Pharmacol. 2002 Jul;62(1):143-53.